Concepedia

Óscar Gerardo Arrieta Rodríguez

ÓG

Statistics

Publications

7

Citations

618

H-Index

7

Active since

1990

Affiliations

Instituto Nacional de Cancerología(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

Centre Léon Bérard

Hospital Universitario Virgen del Rocío

Vanderbilt-Ingram Cancer Center

Óscar Gerardo Arrieta Rodríguez is an author at Instituto Nacional de Cancerología specializing in oncology, cancer therapeutics, and lung cancer.

Top concepts

Publications per year

1990–2024

7

Publications

7

The biomechanical effects of low-intensity ultrasound on healing tendons

Chukuka S. Enwemeka, Óscar Gerardo Arrieta Rodríguez, Sonia Mendosa · Ultrasound in Medicine & Biology · 1990 · 155 citations

, , +7

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

Luis Paz‐Ares, Leora Horn, Hossein Borghaei et al. · Journal of Clinical Oncology · 2015 · 147 citations

, , +15

Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics.

José M. Silva, Gemma Domínguez, Javier Silva et al. · PubMed · 2001 · 137 citations

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 123 citations · Full text

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

Luis Paz‐Ares, Leora Horn, Hossein Borghaei et al. · Journal of Clinical Oncology · 2015 · 33 citations

, , +17

1–5 of 7